Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
Portfolio Pulse from
Calidi Biotherapeutics has announced the start of recruitment for a clinical trial of its immunotherapy product, CLD-101, at Northwestern University Hospital. This trial targets patients with newly diagnosed high-grade glioma.
February 24, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics is initiating recruitment for a clinical trial of its immunotherapy product, CLD-101, at Northwestern University Hospital. This development is significant as it marks progress in their clinical pipeline, potentially enhancing investor confidence.
The commencement of recruitment for the CLD-101 trial is a positive development for Calidi Biotherapeutics as it indicates progress in their clinical pipeline. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100